BM-resident CD69+ TTE may potentially have a beneficial effect against myeloma by recruiting oligoclonal expanded cytotoxic CD69- TTE and maintaining dormancy of the malignant clone. The gene discussed is CD69; the disease is plasma cell myeloma.